New drug cocktail shows promise against aggressive stomach cancer
NCT ID NCT01191697
First seen Nov 03, 2025 · Last updated Jun 13, 2026 · Updated 37 times
Summary
This study tested a combination of chemotherapy (CAPOX) and two targeted antibodies (bevacizumab and trastuzumab) in 37 adults with HER2-positive stomach or esophageal cancer that had spread. The goal was to see how well the treatment shrank tumors and how safe it was. While the approach aimed to control the disease, it is not a cure, as ongoing management is typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.